Alzheimers Disease and other Cognitive Disorders
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Right Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Most Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyAHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?Dementia Risk Rises as Years Lived With Type 2 Diabetes IncreasesHead Injury, Alzheimer's Appear to Affect Brain in Similar WaysResearch Shows Links Between Gum Disease and Alzheimer's
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

'Light Flash' Treatment Might Help Slow Alzheimer's

HealthDay News
by By Alan Mozes HealthDay Reporter
Updated: Jul 27th 2021

new article illustration

TUESDAY, July 27, 2021 (HealthDay News) -- While efforts to develop Alzheimer's medications have so far borne little fruit, new research highlights the therapeutic promise of two non-drug tools: light and sound.

According to a pair of small new studies, exposing Alzheimer's patients to an hour a day of carefully modulated light and/or sound appears, over time, to slow down the telltale brain degeneration that typifies disease progression.

How? By bolstering and reinforcing a particular type of rhythmic brain wave pattern -- called "gamma waves" -- which are known to diminish in power among patients battling Alzheimer's.

"Our completely noninvasive approach to manipulate the power of gamma brain waves works by simply showing mice or people flickering light and buzzing sound at a particular frequency," explained Li-Huei Tsai.

Tsai is director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology. In 2016, she was among a team of researchers who first pioneered testing of this sensory stimulation technique -- nicknamed "GENUS"-- among mice.

That earlier effort yielded encouraging results. After exposing mice with Alzheimer's to visible light flashes at a frequency of 40 Hz, the animal study team found they were able to cut down amyloid beta plaque levels in the brain's visual cortex region.

Amyloid plaque buildup in the brain has long been considered a key sign of Alzheimer's. The specific light flash frequency deployed in the study was designed to match the natural frequency sweet spot of gamma brain waves.

The two new investigations set out to see whether that initial success with mice could be replicated in people.

One was led by Dr. Diane Chan, a neurologist and postdoctoral clinical fellow at MIT, and a member of Tsai's lab.

Chan and her colleagues enlisted 15 patients diagnosed with mild Alzheimer's. Over a three-month period, part of this group was given equipment to self-administer a daily bout of carefully patterned and synchronized light and sound. Each daily session for this treatment group was an hour in length.

As a point of comparison, the other patients were exposed to daily "sham" sessions of constant light and white noise.

Three months out, brain scans revealed that brain wave potency improved in the treatment group, while signs of Alzheimer's-related brain degeneration slowed. The treatment group also performed better on subsequent face and name recognition tests, with no notable side effects.

The second study was led by Mihaly Hajos, a neurophysiologist and professor adjunct at Yale University School of Medicine, and chief scientific officer at Cognito Therapeutics, Inc. in Cambridge, Mass.

Hajos and his colleagues worked with 74 mild-to-moderate Alzheimer's patients. For six months, half the patients underwent similar one-hour daily 40 Hz audio-visual exposure sessions. The other half underwent daily sham sessions.

This team determined that while brain degeneration linked to Alzheimer's did continue to unfold among the treatment group, it did so at a 65% reduced rate when stacked up against the non-treatment group.

Both studies were presented Monday at the Alzheimer's Association annual meeting, being held online and in Denver. Such research is considered preliminary until published in a peer-reviewed journal.

Tsai cautioned that since both investigations involved small groups of patients, more and larger studies will be needed.

Still, she said she was "cautiously optimistic," given that both efforts "indicate that GENUS is safe and people tolerate the treatment well; it preserved the brain volume in Alzheimer's patients; it preserved the connectivity of the brain in Alzheimer's patients, and it preserved some cognitive and daily function in Alzheimer's patients."

Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer's Association, was not part of these studies, and suggested that the exploration of "outside-the-box ideas" of this kind is to be welcomed.

"It is encouraging that we are now seeing Alzheimer's treatment and prevention studies that incorporate a variety of approaches," she noted, "including traditional drug therapies, lifestyle approaches, and non-drug therapeutic elements such as were used in these studies."

At the same time, Edelmayer stressed that as a "relatively novel concept," light and sound therapy is not yet ready for prime time, and "much more research will still be needed to inform whether this could be a safe and effective approach for treatment."

More information

There's more on GENUS research at U.S. National Institute on Aging.

SOURCES: Li-Huei Tsai, PhD, professor, neuroscience, and director, Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge; Rebecca Edelmayer, PhD, senior director, scientific engagement, Alzheimer's Association; Alzheimer's Association annual meeting, Denver and online, July 26-30, 2021

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net